Cargando…

Alcoholic fatty liver disease inhibited the co-expression of Fmo5 and PPARα to activate the NF-κB signaling pathway, thereby reducing liver injury via inducing gut microbiota disturbance

BACKGROUND: Alcohol-induced intestinal dysbiosis disrupts and inflammatory responses are essential in the development of alcoholic fatty liver disease (AFLD). Here, we investigated the effects of Fmo5 on changes in enteric microbiome composition in a model of AFLD and dissected the pathogenic role o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kong, Lingjian, Chen, Jing, Ji, Xiaoli, Qin, Qian, Yang, Huiyu, Liu, Dan, Li, Deliang, Sun, Meiling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788704/ https://www.ncbi.nlm.nih.gov/pubmed/33413501 http://dx.doi.org/10.1186/s13046-020-01782-w

Ejemplares similares

Disturbances in Cholesterol Homeostasis and Non-alcoholic Fatty Liver Diseases
por: Malhotra, Pooja, et al.
Publicado: (2020)

Non-alcoholic fatty liver and the gut microbiota
por: Bashiardes, Stavros, et al.
Publicado: (2016)

Update on Pparγ and Nonalcoholic Fatty Liver Disease
por: Ables, Gene P.
Publicado: (2012)

Short hairpin RNA attenuates liver fibrosis by regulating the PPAR-γ and NF-κB pathways in HBV-induced liver fibrosis in mice
por: Ye, Lei, et al.
Publicado: (2020)

Revisiting the optical properties of the FMO protein
por: Milder, Maaike T. W., et al.
Publicado: (2010)

Hepcidin in non-alcoholic fatty liver disease regulated by the TLR4/NF-κB signaling pathway
por: CHEN, WEI, et al.
Publicado: (2016)

PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients
por: Lange, Naomi F., et al.
Publicado: (2022)

Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Saeed, Ali, et al.
Publicado: (2017)

Discovery of the Odderon by TOTEM experiments and the FMO approach
por: Martynov, Evgenij, et al.
Publicado: (2019)

PPAR γ/Nnat/NF-κB Axis Involved in Promoting Effects of Adiponectin on Preadipocyte Differentiation
por: Yang, Wenkai, et al.
Publicado: (2019)

N-3 PUFA Supplementation Triggers PPAR-α Activation and PPAR-α/NF-κB Interaction: Anti-Inflammatory Implications in Liver Ischemia-Reperfusion Injury
por: Zúñiga, Jessica, et al.
Publicado: (2011)

Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases
por: Sharma, Satya Priya, et al.
Publicado: (2021)

Non-alcoholic fatty liver disease, diet and gut microbiota
por: Finelli, Carmine, et al.
Publicado: (2014)

Myeloid-derived growth factor alleviates non-alcoholic fatty liver disease alleviates in a manner involving IKKβ/NF-κB signaling
por: Ding, Yan, et al.
Publicado: (2023)

A new role for inflammasomes: sensing the disturbances in non-alcoholic fatty liver disease
por: Desai, Poorvi, et al.
Publicado: (2013)

The Role of NF-κB in PPARα-Mediated Hepatocarcinogenesis
por: Glauert, Howard P., et al.
Publicado: (2008)

PPARs and Liver Disease
por: Kondo, Yasuteru, et al.
Publicado: (2013)

Fluorescence-excitation and Emission Spectroscopy on Single FMO Complexes
por: Löhner, Alexander, et al.
Publicado: (2016)

From Non-Alcoholic Fatty Liver Disease to Liver Cancer: Microbiota and Inflammation as Key Players
por: Rodríguez-Lara, Avilene, et al.
Publicado: (2023)

TLRs, NF-κB, JNK, and Liver Regeneration
por: Iimuro, Yuji, et al.
Publicado: (2010)

Gentiopicroside ameliorates CCl(4)-induced liver injury in mice by regulating the PPAR-γ/Nrf2 and NF-κB/IκB signaling pathways
por: Zhang, Yun, et al.
Publicado: (2023)

Role of Microbiota-Derived Metabolites in Alcoholic and Non-Alcoholic Fatty Liver Diseases
por: Park, Ji-Won, et al.
Publicado: (2021)

NFκB/Orai1 Facilitates Endoplasmic Reticulum Stress by Oxidative Stress in the Pathogenesis of Non-alcoholic Fatty Liver Disease
por: Zhang, Bingbing, et al.
Publicado: (2019)

Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease
por: Zhou, Jin, et al.
Publicado: (2021)

PPARγ/NF‐κB and TGF‐β1/Smad pathway are involved in the anti‐fibrotic effects of levo‐tetrahydropalmatine on liver fibrosis
por: Yu, Qiang, et al.
Publicado: (2021)

PPARs as Metabolic Regulators in the Liver: Lessons from Liver-Specific PPAR-Null Mice
por: Wang, Yaping, et al.
Publicado: (2020)

The Protective Effects of Corn Oligopeptides on Acute Alcoholic Liver Disease by Inhibiting the Activation of Kupffer Cells NF-κB/AMPK Signal Pathway
por: Wei, Ying, et al.
Publicado: (2022)

PPARγ contributes to PKM2 and HK2 expression in fatty liver
por: Panasyuk, Ganna, et al.
Publicado: (2012)

Altered Fecal Microbiota Correlates with Liver Biochemistry in Nonobese Patients with Non-alcoholic Fatty Liver Disease
por: Wang, Baohong, et al.
Publicado: (2016)

Production of drug metabolites by human FMO3 in Escherichia coli
por: Catucci, Gianluca, et al.
Publicado: (2020)

FMO4 shapes immuno‐metabolic reconfiguration in hepatocellular carcinoma
por: Luo, Yan, et al.
Publicado: (2022)

Chitosan Oligosaccharides Alleviate Colitis by Regulating Intestinal Microbiota and PPARγ/SIRT1-Mediated NF-κB Pathway
por: Guo, Congcong, et al.
Publicado: (2022)

Corrigendum: NFκB/Orai1 Facilitates Endoplasmic Reticulum Stress by Oxidative Stress in the Pathogenesis of Non-alcoholic Fatty Liver Disease
por: Zhang, Bingbing, et al.
Publicado: (2019)

A PPARγ, NF-κB and AMPK-Dependent Mechanism May Be Involved in the Beneficial Effects of Curcumin in the Diabetic db/db Mice Liver
por: Jiménez-Flores, Lizbeth M., et al.
Publicado: (2014)

Noncanonical NF-κB Signaling Pathway in Liver Diseases
por: Chen, Qianhui, et al.
Publicado: (2021)

Hepatic NF‐κB‐Inducing Kinase and Inhibitor of NF‐κB Kinase Subunit α Promote Liver Oxidative Stress, Ferroptosis, and Liver Injury
por: Zhong, Xiao, et al.
Publicado: (2021)

Causative role of gut microbiota in non-alcoholic fatty liver disease pathogenesis
por: Alisi, Anna, et al.
Publicado: (2012)

Astaxanthin Prevents Alcoholic Fatty Liver Disease by Modulating Mouse Gut Microbiota
por: Liu, Huilin, et al.
Publicado: (2018)

Intestinal Microbiota Modulation in Obesity-Related Non-alcoholic Fatty Liver Disease
por: Porras, David, et al.
Publicado: (2018)

The role of gut microbiota in non-alcoholic fatty liver disease: pathways of mechanisms
por: JASIRWAN, Chyntia Olivia Maurine, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_96ernqr4lf279a26ul6617sng5